Title:
COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/000637
Kind Code:
A1
Abstract:
Provided is a combined pharmaceutical composition for treating a tumor, comprising a CAR-T cell and G-CSF. Also provided is use of the composition in the preparation of a drug for treating a tumor. The combination can significantly improve the amplification time of the CAR-T cell in vivo, promote the reduction of the tumor load, and prolong the efficacy maintenance time of a patient and the survival time of the patient.
Inventors:
KANG LIQING (CN)
XU NAN (CN)
TAN JINGWEN (CN)
LI MINGHAO (CN)
YU ZHOU (CN)
XU NAN (CN)
TAN JINGWEN (CN)
LI MINGHAO (CN)
YU ZHOU (CN)
Application Number:
PCT/CN2022/104961
Publication Date:
January 04, 2024
Filing Date:
July 11, 2022
Export Citation:
Assignee:
SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD (CN)
International Classes:
A61P35/02; A61K38/00; C12N5/00; C12N15/00
Foreign References:
| CN113286811A | 2021-08-20 |
Other References:
ANONYMOUS: "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma", CLINICALTRIALS.GOV ID NCT03579927, 29 January 2020 (2020-01-29), XP093125284, Retrieved from the Internet [retrieved on 20240130]
GALLI EUGENIO; ALLAIN VINCENT; DI BLASI ROBERTA; BERNARD SOPHIE; VERCELLINO LAETITIA; MORIN FLORENCE; MOATTI HANNAH; CAILLAT-ZUCMA: "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma", BONE MARROW TRANSPLANTATION, NATURE PUBLISHING GROUP, GB, vol. 55, no. 12, 1 January 1900 (1900-01-01), GB , pages 2347 - 2349, XP037304357, ISSN: 0268-3369, DOI: 10.1038/s41409-020-01006-x
LIÉVIN, R ET AL.: "Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma", BONE MARROW TRANSPLANTATION, vol. 57, 30 January 2022 (2022-01-30), XP037712071, DOI: 10.1038/s41409-021-01526-0
ABID MUHAMMAD BILAL: "Granulocyte Colony-Stimulating Factor Usage in Recipients of Chimeric Antigen Receptor T-Cell Immunotherapy", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 40, no. 13, 1 May 2022 (2022-05-01), US , pages 1508 - 1509, XP093125286, ISSN: 0732-183X, DOI: 10.1200/JCO.21.02694
BARRETO JASON N, DOLESKI CORINA J, HAYNE JUSTIN R, HATHCOCK MATTHEW A, TRUONG TUAN A, ANSELL STEPHEN M, BENNANI NORA, PALUDO JONAS: "3473 The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel", 62ND ASH ANNUAL MEETING AND EXPOSITION, 7 December 2020 (2020-12-07), pages 1 - 5, XP093125289, [retrieved on 20240130]
HAYDEN P.J., RODDIE C., BADER P., BASAK G.W., BONIG H., BONINI C., CHABANNON C., CICERI F., CORBACIOGLU S., ELLARD R., SANCHEZ-GUI: "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)", ANNALS OF ONCOLOGY, vol. 33, no. 3, 1 March 2022 (2022-03-01), pages 259 - 275, XP093073164, ISSN: 0923-7534, DOI: 10.1016/j.annonc.2021.12.003
SANTOMASSO BIANCA D, NASTOUPIL LORETTA J, ADKINS SHERRY, LACCHETTI CHRISTINA, SCHNEIDER BRYAN J, ANADKAT MILAN, ATKINS MICHAEL B, : "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update", JOURNAL OF CLINICAL ONCOLOGY, vol. 39, 1 November 2021 (2021-11-01), pages 3978 - 3994, XP093125292, DOI: 10.1200/JCO.21
JUAN M U, LI HAI-RONG, JIANG JING-YI, RUI ZHANG, TING YUAN, QI DENG: "CD22 CAR-T salvage therapy for a refractory acute B lymphocytic leukemia patient with TP53 positive mutation and short-term recurrence after remission from CD19 CAR-T therapy", TIANJIN MEDICAL JOURNAL, vol. 48, no. 4, 15 April 2020 (2020-04-15), pages 308 - 312, XP093125297
GALLI EUGENIO; ALLAIN VINCENT; DI BLASI ROBERTA; BERNARD SOPHIE; VERCELLINO LAETITIA; MORIN FLORENCE; MOATTI HANNAH; CAILLAT-ZUCMA: "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma", BONE MARROW TRANSPLANTATION, NATURE PUBLISHING GROUP, GB, vol. 55, no. 12, 1 January 1900 (1900-01-01), GB , pages 2347 - 2349, XP037304357, ISSN: 0268-3369, DOI: 10.1038/s41409-020-01006-x
LIÉVIN, R ET AL.: "Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma", BONE MARROW TRANSPLANTATION, vol. 57, 30 January 2022 (2022-01-30), XP037712071, DOI: 10.1038/s41409-021-01526-0
ABID MUHAMMAD BILAL: "Granulocyte Colony-Stimulating Factor Usage in Recipients of Chimeric Antigen Receptor T-Cell Immunotherapy", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 40, no. 13, 1 May 2022 (2022-05-01), US , pages 1508 - 1509, XP093125286, ISSN: 0732-183X, DOI: 10.1200/JCO.21.02694
BARRETO JASON N, DOLESKI CORINA J, HAYNE JUSTIN R, HATHCOCK MATTHEW A, TRUONG TUAN A, ANSELL STEPHEN M, BENNANI NORA, PALUDO JONAS: "3473 The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel", 62ND ASH ANNUAL MEETING AND EXPOSITION, 7 December 2020 (2020-12-07), pages 1 - 5, XP093125289, [retrieved on 20240130]
HAYDEN P.J., RODDIE C., BADER P., BASAK G.W., BONIG H., BONINI C., CHABANNON C., CICERI F., CORBACIOGLU S., ELLARD R., SANCHEZ-GUI: "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)", ANNALS OF ONCOLOGY, vol. 33, no. 3, 1 March 2022 (2022-03-01), pages 259 - 275, XP093073164, ISSN: 0923-7534, DOI: 10.1016/j.annonc.2021.12.003
SANTOMASSO BIANCA D, NASTOUPIL LORETTA J, ADKINS SHERRY, LACCHETTI CHRISTINA, SCHNEIDER BRYAN J, ANADKAT MILAN, ATKINS MICHAEL B, : "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update", JOURNAL OF CLINICAL ONCOLOGY, vol. 39, 1 November 2021 (2021-11-01), pages 3978 - 3994, XP093125292, DOI: 10.1200/JCO.21
JUAN M U, LI HAI-RONG, JIANG JING-YI, RUI ZHANG, TING YUAN, QI DENG: "CD22 CAR-T salvage therapy for a refractory acute B lymphocytic leukemia patient with TP53 positive mutation and short-term recurrence after remission from CD19 CAR-T therapy", TIANJIN MEDICAL JOURNAL, vol. 48, no. 4, 15 April 2020 (2020-04-15), pages 308 - 312, XP093125297
Attorney, Agent or Firm:
SHANGHAI HUIYE LAW FIRM (CN)
Download PDF: